|  |  |
| --- | --- |
| **Supplementary Table 1. Baseline characteristics and between-group comparisons** |  |
| **Characteristic** | **All** | **Without OILI** | **OILI**  | ***p*** |
| Sex, *n* (%) | Female | 1,199 (36.17) | 1,153 (36.10) | 46 (38.02) | 0.667a |
|  | Male | 2,116 (63.83) | 2,041 (63.90) | 75 (61.98) |  |
| Age in years | Median | 57 | 57 | 64 | 0.000b |
|  | P25–P75 | 49–63 | 49–63 | 54–67 |  |
| Height in cm | Median | 165 | 165 | 165 | 0.087b |
|  | P25–P75 | 160–170 | 160–170 | 156–170 |  |
| Weight in kg | Median | 58 | 58 | 55 | 0.023b |
|  | P25–P75 | 51–64 | 51–64 | 49.5–63 |  |
| BMI | Median | 21.09 | 21.09 | 21.11 | 0.551b |
|  | P25–P75 | 19.31–23 | 19.34–22.99 | 19.03–23.03 |  |
| KPS score | Median | 85 | 90 | 85 | 0.173b |
|  | P25–P75 | 80–90 | 80–90 | 80–90 |  |
| History of hepatitis B, *n* (%) | No | 3,255 (98.19) | 3,139 (98.28) | 116 (95.87) | 0.109c |
|  | Yes | 60 (1.81) | 55 (1.72) | 5 (4.13) |  |
| History of renal calculi, *n* (%) | No | 3,291 (99.28) | 3,174 (99.37) | 117 (96.69) | 0.010d |
|  | Yes | 24 (0.72) | 20 (0.63) | 4 (3.31) |  |
| Comorbidities |  |  |  |  |  |
| Diabetes, *n* (%) | No | 3,140 (94.72) | 3,024 (94.68) | 116 (95.87) | 0.565a |
|  | Yes | 175 (5.28) | 170 (5.32) | 5 (4.13) |  |
| Hypertension, *n* (%) | No | 2,868 (86.52) | 2,765 (86.57) | 103 (85.12) | 0.648a |
|  | Yes | 447 (13.48) | 429 (13.43) | 18 (14.88) |  |
| Cerebral Infarction, *n* (%) | No | 3,277 (98.85) | 3,158 (98.87) | 119 (98.35) | 0.922c |
|  | Yes | 38 (1.15) | 36 (1.13) | 2 (1.65) |  |
| Gastritis, *n* (%) | No | 3,267 (98.55) | 3,151 (98.65) | 116 (95.87) | 0.033c |
|  | Yes | 48 (1.45) | 43 (1.35) | 5 (4.13) |  |
| Duodenal ulcer, *n* (%) | No | 3,302 (99.61) | 3,184 (99.69) | 118 (97.52) | 0.010d |
|  | Yes | 13 (0.39) | 10 (0.31) | 3 (2.48) |  |
| Chemotherapy regimen, *n* (%) | FOLFOX | 1,966 (59.31) | 1,939 (60.71) | 27 (22.31) | 0.000a |
|  | XELOX | 665 (20.06) | 621 (19.44) | 44 (36.36) |  |
|  | GEMOX | 45 (1.36) | 31 (0.97) | 14 (11.57) |  |
|  | SOX | 361 (10.89) | 356 (11.15) | 5 (4.13) |  |
|  | OXA & Raltitrexed | 100(3.02) | 94 (2.94) | 6(4.96) |  |
|  | OXA | 40 (1.21) | 28 (0.88) | 12 (9.92) |  |
|  | Others | 138 (4.16) | 125 (3.91) | 13 (10.74) |  |
| Chemotherapy cycles | Median | 3 | 3 | 4 | 0.007b |
|  | P25–P75 | 2–5 | 2–5 | 2–6 |  |
| Single dose of OXA in mg | Median | 150 | 150 | 150 | 0.826b |
|  | P25–P75 | 123–175 | 123–175 | 120–190 |  |
| Total dose of OXA in mg | Median | 450 | 440 | 600 | 0.016b |
|  | P25–P75 | 230–750 | 230–750 | 230–900 |  |
| Prophylactic drugs |  |  |  |  |  |
| 5-HT3 receptor antagonists, *n* (%) | No | 225 (6.79) | 221 (6.92) | 4 (3.31) | 0.121a |
|  | Yes | 3090 (93.21) | 2973 (93.08) | 117 (96.69) |  |
| Proton pump inhibitors, *n* (%) | No | 1361 (41.06) | 1328 (41.58) | 33 (27.27) | 0.002a |
|  | Yes | 1954 (58.94) | 1866 (58.42) | 88 (72.73) |  |
| Liver protective drugs, *n* (%) | No | 2582 (77.89) | 2494 (78.08) | 88 (72.73) | 0.163a |
|  | Yes | 733 (22.11) | 700 (21.92) | 33 (27.27) |  |
| Glucocorticoid drugs, *n* (%) | No | 2749 (82.93) | 2681 (83.94) | 68 (56.20) | 0.000a |
|  | Yes | 566 (17.07) | 513 (16.06) | 53 (43.80) |  |
| Antihistamine drugs, *n* (%) | No | 2757 (83.17) | 2672 (83.66) | 85 (70.25) | 0.000a |
| 　 | Yes | 558 (16.83) | 522 (16.34) | 36 (29.75) | 　 |
| aPearson's chi-square test; bMann-Whitney *U* test; cContinuity correction; dFisher's exact test. BMI, body mass index; KPS, Karnofsky performance status; OXA, oxaliplatin. |